The new glaucoma treatment ‘Eybelis’ that has been released can now be prescribed at general hospitals in Korea.

According to industry sources, Santen Pharmaceutical Korea’s selective EP2 receptor Eybelis Ophthalmic Solution (Omidenepag Isopropyl) has recently passed the review of drug committees (DC) in two of the ‘Big 5’ major hospitals in Korea - the Seoul National University Hospital and the Samsung Medical Center.

Eybelis is a treatment for open-angle glaucoma and ocular hypertension that contains the active pharmaceutical ingredient omidenepag isopropyl, which has a non-prostaglandin structure that lowers intraocular pressure with a new mechanism of action.

Omide